Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 3Phase 1 2Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 37Recurrence 4Neoplasms 4Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Hematologic Diseases 1Disease 1Breast Neoplasms 1

Interventions

Cyclophosphamide 17Dexamethasone 15Bortezomib 14fludarabine phosphate 12Melphalan 12Lenalidomide 10fludarabine 9Filgrastim 8pomalidomide 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Rituximab 6Radiotherapy 6Etoposide 6Whole-Body Irradiation 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Busulfan 5Antilymphocyte Serum 5sargramostim 4Sirolimus 4Panobinostat 4Mycophenolic Acid 4Methylprednisolone 4Cyclosporine 4carfilzomib 3Vorinostat 3Stem Cell Transplantation 3Prednisone 3Methotrexate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms, Plasma Cell × daratumumab × Clear all
NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

Fate Therapeutics

Phase 1 Completed
31 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04614636 2023-09-21

FT538 in Subjects With Advanced Hematologic Malignancies

Fate Therapeutics

Phase 1 Terminated
42 enrolled
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡